Furthermore, in a SCALE Insulin trial, liraglutide 3.0 mg achieved a mean BWR of 5.8%, versus −1.5% with placebo (estimated treatment difference −4.3% [95% CI -5.5; −3.2]; p < 0.0001), with 51.8% of individuals having a BWR ≥ 5% versus 24.0% with placebo (odds ratio 3.41 [95% CI 2.19; 5.31]; p < 0.0001), in T2DM patients associating insulin treatment [42]; however, liraglutide is approved at a maximum 1.8 mg dose for DM. Here, INS is linked to diabetes mellitus.